CDA | Evidence Driven
CDA | Evidence Driven

Tagrisso for Non-Small Cell Lung Cancer (first line) – Details

Details

Files
Generic Name:
Osimertinib
Project Status:
Complete
Therapeutic Area:
Non-Small Cell Lung Cancer (NSCLC) (first line)
Manufacturer:
AstraZeneca Canada Inc.
Brand Name:
Tagrisso
Project Line:
Reimbursement Review
Project Number:
PC0137-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
40 mg and 80 mg
Tumour Type:
Lung
Indications:
Non-Small Cell Lung Cancer (first line)
Funding Request:
For the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations
Pre Noc Submission:
Yes
Sponsor:
AstraZeneca Canada Inc.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Osimertinib (Tagrisso) NSCLC (first line) – pERC Final Recommendation Final Recommendation January 4, 2019 View PDF
Osimertinib (Tagrisso) NSCLC (first line) - Final Clinical Guidance Report Guidance Reports January 4, 2019 View PDF
Osimertinib (Tagrisso) NSCLC (first line) - Final Economic Guidance Report Guidance Reports January 4, 2019 View PDF
Osimertinib (Tagrisso) NSCLC (first line) - pERC Initial Recommendation Initial Recommendation November 1, 2018 View PDF
Osimertinib (Tagrisso) NSCLC (first line) – PAG Feedback on Initial Recommendation Feedback January 4, 2019 View PDF
Osimertinib (Tagrisso) NSCLC (first line) – Submitter Feedback on Initial Recommendation Feedback January 4, 2019 View PDF
Osimertinib (Tagrisso) NSCLC (first line) – Patient Feedback on Initial Recommendation Feedback January 4, 2019 View PDF
Osimertinib (Tagrisso) NSCLC (first line) – Clinician Feedback on Initial Recommendation Feedback January 4, 2019 View PDF
Osimertinib (Tagrisso) NSCLC (first line) – Patient COI Declarations COI Declarations January 4, 2019 View PDF
Osimertinib (Tagrisso) NSCLC (first line) – Clinician COI Declarations COI Declarations January 4, 2019 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : January 21, 2019